EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma - PubMed (original) (raw)
Comparative Study
. 2003 Feb 20;103(5):657-63.
doi: 10.1002/ijc.10860.
Affiliations
- PMID: 12494475
- DOI: 10.1002/ijc.10860
Comparative Study
EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma
Tatsuya Miyazaki et al. Int J Cancer. 2003.
Abstract
EphA2 is a member of the Eph family of receptor tyrosine kinases, which interact with cell-bound ligands known as ephrins. EphA2 expression was investigated by immunohistochemistry with an anti-EphA2 monoclonal antibody in 80 patients with esophageal squamous cell carcinoma (ESCC) who had undergone surgery. EphA2 overexpression was positive in 40 of the 80 patients (50%). A significant correlation was observed between EphA2 expression and regional lymph node metastasis (p=0.023), number of lymph node metastases (p=0.011) and poor degree of tumor differentiation (p=0.004). The survival rates of EphA2-positive patients were poorer than those of EphA2-negative patients (p=0.014). The 5-year survival rate of patients without EphA2 overexpression was 68%, whereas that of patients with EphA2 overexpression was 29%. EphA2 expression was also investigated in 7 ESCC cell lines (TE-1, -2, -8, -13, -15, TT and TTn) and 1 immortalized human esophageal keratinocyte cell line (CHEK-1). Western blotting revealed different levels of EphA2 expression in the 8 cell lines. EphA2 was expressed at a high level in the ESCC cell lines compared to CHEK-1. EphA2 phosphorylation was demonstrated in all cell lines. Northern blot analysis showed that EphA2 mRNA expression in TE-1 was greater than that in the other ESCC cell lines. The observation of small gaps on Western blot analysis of the ESCC cell lines suggests that there may be a mechanism for EphA2 regulation at the point of translation. In conclusion, EphA2 overexpression appears to be related to poor degree of tumor differentiation and lymph node metastasis in ESCC. Consequently, patients with EphA2 overexpression have a poorer prognosis than those without. EphA2 is a potential target to prevent ESCC cells spreading into the lymphatic drainage.
Copyright 2002 Wiley-Liss, Inc.
Similar articles
- FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma.
Miyazaki T, Kato H, Nakajima M, Sohda M, Fukai Y, Masuda N, Manda R, Fukuchi M, Tsukada K, Kuwano H. Miyazaki T, et al. Br J Cancer. 2003 Jul 7;89(1):140-5. doi: 10.1038/sj.bjc.6601050. Br J Cancer. 2003. PMID: 12838315 Free PMC article. - Expression of lysyl oxidase is correlated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma.
Sakai M, Kato H, Sano A, Tanaka N, Inose T, Kimura H, Sohda M, Nakajima M, Kuwano H. Sakai M, et al. Ann Surg Oncol. 2009 Sep;16(9):2494-501. doi: 10.1245/s10434-009-0559-5. Epub 2009 Jun 13. Ann Surg Oncol. 2009. PMID: 19526206 - Overexpression of Sirtuin-1 is associated with poor clinical outcome in esophageal squamous cell carcinoma.
He Z, Yi J, Jin L, Pan B, Chen L, Song H. He Z, et al. Tumour Biol. 2016 Jun;37(6):7139-48. doi: 10.1007/s13277-015-4459-y. Epub 2015 Dec 12. Tumour Biol. 2016. PMID: 26662958 - The Functions of EphA1 Receptor Tyrosine Kinase in Several Tumors.
Wu Y, Du Z, Mou J, Qiu X, Chen J, Cai S, Ren D, Xiao F, Zhou G, Yuan C. Wu Y, et al. Curr Med Chem. 2023;30(20):2340-2353. doi: 10.2174/0929867329666220820125638. Curr Med Chem. 2023. PMID: 35996244 Review. - The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.
Wykosky J, Debinski W. Wykosky J, et al. Mol Cancer Res. 2008 Dec;6(12):1795-806. doi: 10.1158/1541-7786.MCR-08-0244. Mol Cancer Res. 2008. PMID: 19074825 Free PMC article. Review.
Cited by
- A spatiotemporal comparative analysis on tumor immune microenvironment characteristics between neoadjuvant chemotherapy and preoperative immunotherapy for ESCC.
Zhou Z, Zhang H, Du J, Yang J, Pan W, Zhang Q, Wang H, Tang P, Ba Y, Zhang H. Zhou Z, et al. Cell Death Dis. 2024 Sep 10;15(9):663. doi: 10.1038/s41419-024-06986-y. Cell Death Dis. 2024. PMID: 39256364 Free PMC article. - Targeting the EphA2 pathway: could it be the way for bone sarcomas?
Giordano G, Tucciarello C, Merlini A, Cutrupi S, Pignochino Y. Giordano G, et al. Cell Commun Signal. 2024 Sep 9;22(1):433. doi: 10.1186/s12964-024-01811-7. Cell Commun Signal. 2024. PMID: 39252029 Free PMC article. Review. - Advancing Esophageal Cancer Treatment: Immunotherapy in Neoadjuvant and Adjuvant Settings.
Park D, Jeon WJ, Yang C, Castillo DR. Park D, et al. Cancers (Basel). 2024 Jan 11;16(2):318. doi: 10.3390/cancers16020318. Cancers (Basel). 2024. PMID: 38254805 Free PMC article. Review. - Downregulation of EphA2 stability by RNF5 limits its tumor-suppressive function in HER2-negative breast cancers.
Li X, Wang F, Huang L, Yang M, Kuang E. Li X, et al. Cell Death Dis. 2023 Oct 10;14(10):662. doi: 10.1038/s41419-023-06188-y. Cell Death Dis. 2023. PMID: 37816703 Free PMC article. - Combination of protein and cell internalization SELEX identifies a potential RNA therapeutic and delivery platform to treat EphA2-expressing tumors.
Santana-Viera L, Dassie JP, Rosàs-Lapeña M, Garcia-Monclús S, Chicón-Bosch M, Pérez-Capó M, Pozo LD, Sanchez-Serra S, Almacellas-Rabaiget O, Maqueda-Marcos S, López-Alemany R, Thiel WH, Giangrande PH, Tirado OM. Santana-Viera L, et al. Mol Ther Nucleic Acids. 2023 May 8;32:758-772. doi: 10.1016/j.omtn.2023.05.003. eCollection 2023 Jun 13. Mol Ther Nucleic Acids. 2023. PMID: 37251690 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous